Discover and read the best of Twitter Threads about #tils
Most recents (3)
1/6
I would think as #TILS move through the process to demerge Accustem Sciences, the SP should start to trend higher.
Today's RNS confirms the easy bit with the court hearings being the true barrier, be it I see little problem in getting through them.
I would think as #TILS move through the process to demerge Accustem Sciences, the SP should start to trend higher.
Today's RNS confirms the easy bit with the court hearings being the true barrier, be it I see little problem in getting through them.
2/6
I don't buy a £280m IPO valuation because they won't have a test ready for market. Whilst the CE Mark process is 'planned' to begin in November 2020, it won't be completed until well after the IPO.
However, I am certainly enthused by Executive Chairman Gabriele Cerrone's
I don't buy a £280m IPO valuation because they won't have a test ready for market. Whilst the CE Mark process is 'planned' to begin in November 2020, it won't be completed until well after the IPO.
However, I am certainly enthused by Executive Chairman Gabriele Cerrone's
3/6
"beneficial interest" in the c. 33% of TILS, that is owned by Planwise Group LTD.
What that says is that the push will certainly be on, to maximise the IPO and minimise the dilution required.
I talk about dilution because it will inevitably come with the IPO,
"beneficial interest" in the c. 33% of TILS, that is owned by Planwise Group LTD.
What that says is that the push will certainly be on, to maximise the IPO and minimise the dilution required.
I talk about dilution because it will inevitably come with the IPO,
1/13
Been focused on other things for a few days but a few thoughts on shares I hold, given the perceived turmoil.
Main focuses for me for a while now, has been shares exposed to Covid, battery metals (incl. energy storage) and gold.
#HZM #BCN #ACP #GDR #AVCT #SRB #BMN
Been focused on other things for a few days but a few thoughts on shares I hold, given the perceived turmoil.
Main focuses for me for a while now, has been shares exposed to Covid, battery metals (incl. energy storage) and gold.
#HZM #BCN #ACP #GDR #AVCT #SRB #BMN
2/13
The events of the last few days if anything strengthen that stance.
In terms of Covid (and I tread carefully because both my stocks have other things in their locker), its a waiting game on both.
I think 1 strong update from #GDR and it moves much higher from here.
The events of the last few days if anything strengthen that stance.
In terms of Covid (and I tread carefully because both my stocks have other things in their locker), its a waiting game on both.
I think 1 strong update from #GDR and it moves much higher from here.
3/13
In terms of #AVCT, an update, one way or the other is pending, whereby the exact progress of BAMS/LFT tests, should be made clearer.
I see no reason for concern and the lockdown measures announced today in the UK, only go to strengthen that argument. Nothing has changed.
In terms of #AVCT, an update, one way or the other is pending, whereby the exact progress of BAMS/LFT tests, should be made clearer.
I see no reason for concern and the lockdown measures announced today in the UK, only go to strengthen that argument. Nothing has changed.
Well its certainly not boring being a #TILS shareholder these days.
What I like about this company is the tenacity and willingness from management, to think outside the box and just get things done.
Really significant couple of days in the life of TILS.
What I like about this company is the tenacity and willingness from management, to think outside the box and just get things done.
Really significant couple of days in the life of TILS.
1A
Following today's unexpected announcement from #TILS, the company now has a very busy period over the next 6-9 months, with 3 Foralumab trials in play and a series of interim analysis results/results, due during the above time period.
Milciclib could then follow shortly. .
Following today's unexpected announcement from #TILS, the company now has a very busy period over the next 6-9 months, with 3 Foralumab trials in play and a series of interim analysis results/results, due during the above time period.
Milciclib could then follow shortly. .
1B
. . behind with the StemPrintER demerger sandwiched in between it all.
Gabriel Cerrone stated in today's interview, that the company is funded for the next couple of years (StemPrintER aside, which will clearly raise on IPO), so that signals a free run at all of the above.
. . behind with the StemPrintER demerger sandwiched in between it all.
Gabriel Cerrone stated in today's interview, that the company is funded for the next couple of years (StemPrintER aside, which will clearly raise on IPO), so that signals a free run at all of the above.
